Abstract
Galectin-1 (Gal-1), a homodimeric prototype of the galectins with a single carbohydrate-recognition domain, was recently identified as being overexpressed in tumor-associated capillary endothelial cells. The role of Gal-1 in endothelial cellular functions and the mechanism of action of Gal-1 remain unknown. Neuropilin-1 (NRP1) is a neuronal receptor that mediates repulsive growth cone guidance, and NRP1 functions in endothelial cells as a coreceptor (with vascular endothelial growth factor receptors (VEGFRs)) for VEGF165. In this study, we found that Gal-1 was overexpressed in the tumor-associated endothelial cells of oral squamous cell carcinomas (P<0.001). Gal-1 increased the proliferation and adhesion of endothelial cells, and enhanced cell migration in combination with VEGF165. Surprisingly, Gal-1 selectively bound NRP1 via the carbohydrate-recognition domain, but did not bind VEGFR-1, VEGFR-2 or VEGFR-3. The Gal-1–NRP1 interaction mediated the migration and adhesion of endothelial cells. The binding of Gal-1 to NRP1 enhanced VEGFR-2 phosphorylation and stimulated the activation of the mitogen activated protein (MAP) kinases SAPK1/JNK (stress activated protein kinase-1/c-Jun NH2-terminal kinase). These findings show, for the first time, that Gal-1 can directly bind to NRP1 on endothelial cells, and can promote the NRP1/VEGFR-2-mediated signaling pathway as well as NRP1-mediated biological activities.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Camby I, Le Mercier M, Lefranc F, Kiss R . (2006). Galectin-1: a small protein with major functions. Glycobiology 16: 137R–157R.
Castro-Rivera E, Ran S, Thorpe P, Minna JD . (2004). Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci USA 101: 11432–11437.
Chiang WF, Liu SY, Fang LY, Lin CN, Wu MH, Chen YC et al. (2007). Overexpression of galectin-1 at the tumor invasion front is associated with poor prognosis in early-stage oral squamous cell carcinoma. Oral Oncol (in press).
Clausse N, van den Brule F, Waltregny D, Garnier F, Castronovo V . (1999). Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion. Angiogenesis 3: 317–325.
Elola MT, Chiesa ME, Alberti AF, Mordoh J, Fink NE . (2005). Galectin-1 receptors in different cell types. J Biomed Sci 12: 13–29.
Ferrara N, Gerber HP, LeCouter J . (2003). The biology of VEGF and its receptors. Nat Med 9: 669–676.
Fischer C, Sanchez-Ruderisch H, Welzel M, Wiedenmann B, Sakai T, André S et al. (2005). Galectin-1 interacts with the {alpha. J Biol Chem 280: 37266–37277.
Fons P, Herault JP, Delesque N, Tuyaret J, Bono F, Herbert JM . (2004). VEGF-R2 and neuropilin-1 are involved in VEGF-A-induced differentiation of human bone marrow progenitor cells. J Cell Physiol 200: 351–359.
Gaudet AD, Steeves JD, Tetzlaff W, Ramer MS . (2005). Expression and functions of galectin-1 in sensory and motoneurons. Curr Drug Targets 6: 419–425.
Glinsky VV, Huflejt ME, Glinsky GV, Deutscher SL, Quinn TP . (2000). Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on beta- galactoside-mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells. Cancer Res 60: 2584–2588.
Gu M, Wang W, Song WK, Cooper DN, Kaufman SJ . (1994). Selective modulation of the interaction of alpha 7 beta 1 integrin with fibronectin and laminin by L-14 lectin during skeletal muscle differentiation. J Cell Sci 107: 175–181.
He J, Baum LG . (2006). Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration. Lab Invest 86: 578–590.
Hong TM, Chen YL, Wu YY, Yuan A, Chao YC, Chung YC et al. (2007). Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin Cancer Res 13: 4759–4768.
Hu B, Guo P, Bar-Joseph I, Imanishi Y, Jarzynka MJ, Bogler O et al. (2007). Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene 26: 5577–5586.
Jung EJ, Moon HG, Cho BI, Jeong CY, Joo YT, Lee YJ et al. (2007). Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 120: 2331–2338.
Kadri T, Lataillade JJ, Doucet C, Marie A, Ernou I, Bourin P et al. (2005). Proteomic study of Galectin-1 expression in human mesenchymal stem cells. Stem Cells Dev 14: 204–212.
Konigsberg W, Kirchhofer D, Riederer MA, Nemerson Y . (2001). The TF:VIIa complex: clinical significance, structure-function relationships and its role in signaling and metastasis. Thromb Haemost 86: 757–771.
Murga M, Fernandez-Capetillo O, Tosato G . (2005). Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood 105: 1992–1999.
Neufeld G, Cohen T, Shraga N, Lange T, Kessler O, Herzog Y . (2002). The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc Med 12: 13–19.
Ozeki Y, Matsui T, Yamamoto Y, Funahashi M, Hamako J, Titani K . (1995). Tissue fibronectin is an endogenous ligand for galectin-1. Glycobiology 5: 255–261.
Parsons-Wingerter P, Kasman IM, Norberg S, Magnussen A, Zanivan S, Rissone A et al. (2005). Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors. Am J Pathol 167: 193–211.
Rabinovich GA . (2005). Galectin-1 as a potential cancer target. Br J Cancer 92: 1188–1192.
Rorive S, Belot N, Decaestecker C, Lefranc F, Gordower L, Micik S et al. (2001). Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia 33: 241–255.
Shintani Y, Takashima S, Asano Y, Kato H, Liao Y, Yamazaki S et al. (2006). Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2 signaling. EMBO J 25: 3045–3055.
Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S . (2006). Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 103: 15975–15980.
Toscano MA, Bianco GA, Ilarregui JM, Croci DO, Correale J, Hernandez JD et al. (2007). Differential glycosylation of T(H)1, T(H)2 and T(H)-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 8: 825–834.
Vaisman N, Gospodarowicz D, Neufeld G . (1990). Characterization of the receptors for vascular endothelial growth factor. J Biol Chem 265: 19461–19466.
Valenzuela HF, Pace KE, Cabrera PV, White R, Porvari K, Kaija H et al. (2007). O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1. Cancer Res 67: 6155–6162.
van den Brule FA, Waltregny D, Castronovo V . (2001). Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J Pathol 193: 80–87.
Zhou Q, Cummings RD . (1993). L-14 lectin recognition of laminin and its promotion of in vitro cell adhesion. Arch Biochem Biophys 300: 6–17.
Acknowledgements
This study was supported in part by grants NSC-96-2311-B-006-005-MY3 and NSC-95-2314-B-002-119-MY3 from the National Science Council, DOH-TD-B-111-004 from the Department of Health, CMFHR9405 and CMFHR9542 from the Chi-Mei Medical Center, by funds from a Taiwan Government program promoting academic excellence and the development of world-class research centers, and the Landmark Project of National Cheng Kung University, Taiwan.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Hsieh, S., Ying, N., Wu, M. et al. Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene 27, 3746–3753 (2008). https://doi.org/10.1038/sj.onc.1211029
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1211029
Keywords
This article is cited by
-
Galectin-1 Contributes to Vascular Remodeling and Blood Flow Recovery After Cerebral Ischemia in Mice
Translational Stroke Research (2022)
-
The role of circulating galectin-1 in type 2 diabetes and chronic kidney disease: evidence from cross-sectional, longitudinal and Mendelian randomisation analyses
Diabetologia (2022)
-
Angiogenic gene networks are dysregulated in opioid use disorder: evidence from multi-omics and imaging of postmortem human brain
Molecular Psychiatry (2021)
-
Characterization of a neutralizing anti-human galectin-1 monoclonal antibody with angioregulatory and immunomodulatory activities
Angiogenesis (2021)
-
Developmental programming in human umbilical cord vein endothelial cells following fetal growth restriction
Clinical Epigenetics (2020)